share_log

Possible Signal As Novavax Insiders Sell US$713k In Stock

Possible Signal As Novavax Insiders Sell US$713k In Stock

隨着諾瓦瓦克斯醫藥內部人士賣出71.3萬美元的股票,可能出現信號
Simply Wall St ·  01/07 19:53

Despite the fact that Novavax, Inc. (NASDAQ:NVAX) stock rose 23% last week, insiders who sold US$713k worth of stock in the previous 12 months are likely to be better off. Selling at an average price of US$12.54, which is higher than the current price, may have been the wisest decision for these insiders as their investment would have been worth less now than when they sold.

儘管諾瓦瓦克斯醫藥(納斯達克:NVAX)股票上週上漲了23%,但在過去12個月內出售了71.3萬美元股票的內部人士可能會更好。以每股12.54美元的平均價格出售,比當前價格要高,這對這些內部人士來說可能是明智的決定,因爲他們的投資現在的價值比出售時要低。

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

雖然內部交易在長期投資中並不是最重要的,但是我們認爲關注內部人士的動向是完全合理的。

Novavax Insider Transactions Over The Last Year

諾瓦瓦克斯醫藥過去一年的內部交易

The insider, Filip Dubovsky, made the biggest insider sale in the last 12 months. That single transaction was for US$384k worth of shares at a price of US$13.90 each. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$9.76. So it may not shed much light on insider confidence at current levels.

內部人士Filip Dubovsky在過去12個月內進行了最大規模的內部銷售。那筆單筆交易價值38.4萬美元,每股價格爲13.90美元。雖然內部人士的出售是負面的,但對我們來說,如果以更低的價格出售股票,則更顯負面。值得安慰的是,這項交易的價格遠高於目前的股票價格9.76美元。因此,這可能不會對當前水平的內部人士信心產生太多影響。

In total, Novavax insiders sold more than they bought over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

總的來說,諾瓦瓦克斯醫藥的內部人士在過去一年中賣出的股票比買入的多。你可以在下面看到過去12個月內內部交易(由公司和個人進行)的可視化表示。點擊下面的圖表,你可以查看每筆內部交易的準確細節!

big
NasdaqGS:NVAX Insider Trading Volume January 7th 2025
納斯達克GS:NVAX 內部交易成交量 2025年1月7日

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

如果你喜歡買入內部人士正在買入而不是賣出的股票,那麼你可能會喜歡這份免費的公司名單。(提示:他們中的大多數正處於雷達之外)。

Insiders At Novavax Have Sold Stock Recently

諾瓦瓦克斯的內部人最近出售了股票

Over the last three months, we've seen significant insider selling at Novavax. In total, insiders sold US$120k worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain.

在過去三個月中,我們看到諾瓦瓦克斯的內部人進行了大量拋售。在此期間,總共內部人出售了價值12萬美元的股票,我們沒有記錄到任何的購買。考慮到這一點,很難說所有內部人都認爲這些股票很划算。

Insider Ownership

內部持股

Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. From looking at our data, insiders own US$4.4m worth of Novavax stock, about 0.3% of the company. We prefer to see high levels of insider ownership.

許多投資者喜歡查看內部人員持有公司股份的比例。我認爲如果內部人員持有公司大量股份,那是個好跡象。根據我們的數據,內部人員持有價值440萬美元的諾瓦瓦克斯醫藥股票,約佔公司0.3%。我們更希望看到高比例的內部持股。

So What Do The Novavax Insider Transactions Indicate?

那麼諾瓦瓦克斯醫藥的內部交易意味着什麼?

Insiders haven't bought Novavax stock in the last three months, but there was some selling. Despite some insider buying, the longer term picture doesn't make us feel much more positive. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. So we're not rushing to buy, to say the least. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. When we did our research, we found 2 warning signs for Novavax (1 is concerning!) that we believe deserve your full attention.

內部人員在過去三個月沒有買入諾瓦瓦克斯醫藥股票,但有一些賣出行爲。儘管有一些內部買入,長遠來看,這並沒有讓我們感到更積極。內部人員在公司持有的股份相對較少,考慮到賣出情況,我們對這隻股票並不特別興奮。因此,我們並沒有急於買入。至於其他方面,了解內部人員在買入或賣出方面的動態是有幫助的,但了解一家特定公司面臨的風險也是很重要的。當我們進行研究時,我們發現諾瓦瓦克斯醫藥存在兩個警告信號(一個非常值得關注!),我們認爲這些信號值得你充分重視。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然,您也可能會在其他地方找到一個絕佳的投資。請查看這個免費的有趣公司名單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

在本文中,內部人士是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論